• Genetics: Autosomal recessive inheritance; both parents must carry a pathogenic variant in the F11 gene.
• Prevalence: Estimated at 1 in 1 million overall, but higher in certain regions—up to 1 in 500 in Ashkenazi Jewish populations (where a founder mutation is common).¹
• Typical age of presentation: Childhood or early adulthood, but many individuals remain undiagnosed until a bleeding challenge (e.g., surgery) occurs.

Symptoms

Bleeding severity varies widely, even among members of the same family. The most common manifestations include:

Spontaneous or Provoked Bleeding

• Nosebleeds (epistaxis): Frequent, often lasting longer than usual.
• Oral bleeding: Gums bleed after brushing or dental procedures.
• Menorrhagia: Heavy menstrual periods in women; may require supplemental iron.
• Post‑operative bleeding: Delayed bleeding 24–48 hours after surgery, especially in areas rich in fibrinolytic activity (e.g., urologic, oral, or ENT procedures).
• Hematuria: Blood in the urine after catheterization or kidney stone passage.
• Joint and muscle bleeds: Less common than in hemophilia A/B but can occur after significant trauma.
• Bruising (purpura): Easy bruising with minimal trauma.

Less Common Presentations

• Gastrointestinal bleeding (melena or hematochezia) after endoscopic procedures.
• Intracranial hemorrhage – rare but reported after head injury.
• Bleeding from surgical drains or wound sites lasting >5 days.

Causes and Risk Factors

Genetic Basis

Mutations in the F11 gene on chromosome 4q35 reduce the amount or function of factor XI. Over 150 variants are known, ranging from missense mutations to large deletions. The most frequent mutation in Ashkenazi Jews is a single‑base substitution (c.403G>A) that produces a severely reduced plasma FXI level.

Risk Factors

• Having two carrier parents (each with one defective F11 allele).
• Consanguineous marriage, which raises the chance of both parents carrying the same rare variant.
• Ethnic background with known founder mutations (e.g., Ashkenazi Jewish).
• Prior unexplained bleeding after surgeries or dental work.

Diagnosis

Because bleeding can be mild, diagnosis often follows an unexpected hemorrhagic event. A stepwise approach is recommended.

Screening Laboratory Tests

• APTT (activated partial thromboplastin time): Often prolonged, but may be normal in mild cases.
• PT (prothrombin time): Typically normal because the extrinsic pathway is unaffected.
• Platelet count and function: Normal; helps exclude other causes.

Specific Factor Assays

• Factor XI activity assay: Quantifies FXI level (expressed as % of normal). Severe deficiency << 5 %, moderate 5‑30 %, mild >30 %.
• Mixing studies: Patient plasma mixed with normal plasma; correction of APTT suggests a factor deficiency rather than an inhibitor.

Genetic Testing

DNA sequencing of F11 confirms the diagnosis, informs carrier testing, and assists with prenatal counseling. Testing is recommended for:

• Individuals with confirmed low FXII activity.
• Family members of an affected person.
• Couples planning pregnancy when a known carrier is identified.

Imaging (when indicated)

If joint or internal bleeding is suspected, ultrasound, MRI, or CT may be ordered, but these are not diagnostic for the disorder itself.

Treatment Options

Treatment aims to prevent or control bleeding while minimizing exposure to blood products.

Replacement Therapy

• Plasma‑derived FXI concentrate (e.g., Fibrynol or Factick): Preferred for on‑demand therapy; dosing 20–40 IU/kg raises FXI levels sufficiently for most procedures.
• Fresh frozen plasma (FFP): Widely available; provides ~1 IU/mL of FXI. Requires larger volume (≈10–15 mL/kg) and carries risk of volume overload and pathogen transmission.

Antifibrinolytic Agents

Because FXI deficiency is especially problematic in fibrinolysis‑rich sites, drugs that inhibit fibrinolysis are valuable adjuncts.

• Tranexamic acid (TXA): 10–15 mg/kg IV or PO every 8 hours for 5–7 days after surgery.
• Aminocaproic acid: Alternative when TXA is contraindicated.

Prophylactic Strategies

Routine prophylaxis (regular factor replacement) is not standard due to the milder bleeding phenotype, but high‑risk individuals (e.g., frequent surgeries or recurrent menorrhagia) may benefit.

Hemostatic Support for Specific Situations

• Dental procedures: Pre‑treatment with FXI concentrate or FFP + TXA.
• Obstetric care: Delivery in a center with hemophilia expertise; consider FXI concentrate before cesarean section.
• Menstrual management: Hormonal contraceptives, TXA during menses, or occasional FXI replacement for severe cases.

Emerging Therapies

Gene‑editing (CRISPR‑Cas9) and RNA‑based silencing of anticoagulant pathways are in early research phases. No FDA‑approved gene therapy exists for FXI deficiency as of 2026.

Lifestyle Modifications

• Avoidance of contact sports or activities with high trauma risk.
• Prompt treatment of cuts and abrasions.
• Use of protective gear (helmets, padding).

Living with J‑Type Hemophilia (Factor XI Deficiency)

Daily Management Tips

• Medical alert identification: Wear a bracelet or necklace stating “Factor XI Deficiency – requires replacement therapy.”
• Keep a bleeding diary: Record any bleeding episodes, triggers, and treatments; share with your hematologist.
• Regular follow‑up: At least once a year with a hemophilia specialist to review factor levels, treatment plan, and vaccination status.
• Dental hygiene: Soft‑bristled toothbrush, daily floss, and routine dental visits with your dentist informed of the condition.
• Women’s health: Discuss menstrual management and pregnancy planning early with an obstetrician‑hemophilia team.
• Vaccinations: No special contraindications, but avoid intramuscular injections in large muscles unless preceded by factor replacement.

Psychosocial Support

Living with a rare bleeding disorder can cause anxiety. Access to patient advocacy groups (e.g., the Rare Bleeding Disorders Alliance) and counseling services improves quality of life.

Prevention

While the genetic basis cannot be altered, several measures reduce bleeding risk:

• Pre‑operative planning: Inform surgeons and anesthesiologists well in advance; schedule factor replacement 30‑60 minutes before incision.
• Avoid NSAIDs: Non‑steroidal anti‑inflammatory drugs inhibit platelet function and increase bleeding; use acetaminophen for pain when possible.
• Prompt treatment of infections: Upper respiratory infections can exacerbate nasal bleeding; treat early.
• Genetic counseling: For carriers and affected individuals planning families, counseling clarifies recurrence risk and offers prenatal or pre‑implantation testing options.

Complications

If not appropriately managed, FXI deficiency can lead to:

• Chronic anemia: Recurrent menorrhagia or gastrointestinal bleeds may cause iron‑deficiency anemia.
• Joint damage: Repeated hemarthroses (though uncommon) can cause arthropathy.
• Post‑operative hemorrhage: Can be life‑threatening, especially after major abdominal or neurosurgical procedures.
• Intracranial bleeding: Rare but carries high morbidity.
• Psychological impact: Anxiety, depression, or social isolation related to bleeding risk.

When to Seek Emergency Care

References

1. National Hemophilia Foundation. “Factor XI Deficiency (Hemophilia C).” 2023. https://www.hemophilia.org
2. Mayo Clinic. “Factor XI deficiency.” Updated 2024. https://www.mayoclinic.org
3. World Federation of Hemophilia. “Rare Bleeding Disorders.” 2022. https://www.wfh.org
4. U.S. National Library of Medicine. “F11 gene.” GeneReviews®; 2023. https://www.ncbi.nlm.nih.gov/books/NBK1245/
5. Cleveland Clinic. “Hemophilia and other bleeding disorders.” 2024. https://my.clevelandclinic.org
6. American Society of Hematology. “Guidelines for the Management of Factor XI Deficiency.” 2023. https://www.ashgeneral.org